Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab.
暂无分享,去创建一个
S. F. Carbone | P. Tassone | P. Tagliaferri | M. Caraglia | M. Mazzei | V. Barbieri | A. Giudice | L. Pirtoli | A. Reginelli | C. Botta | S. Cappabianca | P. Correale | A. Luce | V. Nardone | P. Tini | P. Pastina | Grazia Calabrese | Carmela Tebala | C. Guida | R. Capasso | R. Giannicola
[1] P. Tassone,et al. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. , 2019, Molecular and clinical oncology.
[2] A. Giordano,et al. Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases , 2019, Strahlentherapie und Onkologie.
[3] Xianming Fan,et al. Effects of different metastasis patterns, surgery and other factors on the prognosis of patients with stage IV non-small cell lung cancer: A Surveillance, Epidemiology, and End Results (SEER) linked database analysis , 2019, Oncology letters.
[4] R. Jeraj,et al. Quantitative FDG PET/CT may help risk-stratify early-stage non-small cell lung cancer patients at risk for recurrence following anatomic resection. , 2019, Journal of thoracic disease.
[5] H. Aerts,et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] S. F. Carbone,et al. Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation , 2019, Gastroenterology research and practice.
[7] P. Tagliaferri,et al. How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies , 2018, Front. Immunol..
[8] Maria Antonietta Mazzei,et al. The role of delta radiomics in gastric cancer. , 2018, Quantitative imaging in medicine and surgery.
[9] R. Valicenti,et al. Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer , 2018, Technology in cancer research & treatment.
[10] A. Madabhushi,et al. Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[11] A. Giordano,et al. The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer , 2018, Expert review of anticancer therapy.
[12] S. F. Carbone,et al. 3D bone texture analysis as a potential predictor of radiation-induced insufficiency fractures. , 2018, Quantitative imaging in medicine and surgery.
[13] Maria Antonietta Mazzei,et al. Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT , 2018, La radiologia medica.
[14] Caramella Caroline,et al. Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study , 2017, Oncotarget.
[15] E. Felip,et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] K. Miles,et al. Can CT measures of tumour heterogeneity stratify risk for nodal metastasis in patients with non-small cell lung cancer? , 2017, Clinical radiology.
[17] P. Tassone,et al. Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. , 2017, Journal of thoracic disease.
[18] P. Tassone,et al. Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev) , 2017, Oncotarget.
[19] Olivier Gevaert,et al. Non–Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications , 2017, Radiology.
[20] M. Anzidei,et al. Analysis of CT features and quantitative texture analysis in patients with lung adenocarcinoma: a correlation with EGFR mutations and survival rates. , 2017, Clinical radiology.
[21] Peter Balter,et al. Delta-radiomics features for the prediction of patient outcomes in non–small cell lung cancer , 2017, Scientific Reports.
[22] Gregory Riely,et al. Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations? , 2017, Clinical imaging.
[23] S. F. Carbone,et al. Bone texture analysis using CT-simulation scans to individuate risk parameters for radiation-induced insufficiency fractures , 2017, Osteoporosis International.
[24] Y. Liu,et al. Tumor heterogeneity assessed by texture analysis on contrast-enhanced CT in lung adenocarcinoma: association with pathologic grade , 2017, Oncotarget.
[25] Maria Antonietta Mazzei,et al. Texture analysis of parotid gland as a predictive factor of radiation induced xerostomia: A subset analysis. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[26] J. Choi,et al. Pathologic stratification of operable lung adenocarcinoma using radiomics features extracted from dual energy CT images , 2016, Oncotarget.
[27] Y. Liu,et al. Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas. , 2016, Clinical lung cancer.
[28] Raymond H Mak,et al. Radiomic phenotype features predict pathological response in non-small cell lung cancer. , 2016, Radiotherapy and Oncology.
[29] Kenneth A. Miles,et al. How to use CT texture analysis for prognostication of non-small cell lung cancer , 2016, Cancer Imaging.
[30] Aaron D Ward,et al. Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy , 2015, Journal of medical imaging.
[31] P. Lambin,et al. Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[32] Robert J. Gillies,et al. Quantitative Computed Tomographic Descriptors Associate Tumor Shape Complexity and Intratumor Heterogeneity with Prognosis in Lung Adenocarcinoma , 2015, PloS one.
[33] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[34] H. Pyo,et al. Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy , 2015, Cancer research and treatment : official journal of Korean Cancer Association.
[35] G. Pilkington,et al. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer , 2015, Thorax.
[36] P. Ott,et al. PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma , 2015, Oncotarget.
[37] A Nisbet,et al. The role of texture analysis in imaging as an outcome predictor and potential tool in radiotherapy treatment planning. , 2014, The British journal of radiology.
[38] Aaron D Ward,et al. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. , 2014, Medical physics.
[39] Ho Yun Lee,et al. Histopathology of lung adenocarcinoma based on new IASLC/ATS/ERS classification: Prognostic stratification with functional and metabolic imaging biomarkers , 2013, Journal of magnetic resonance imaging : JMRI.
[40] J. Seo,et al. Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response? , 2012, Korean journal of radiology.
[41] Johannes A Langendijk,et al. Multivariate modeling of complications with data driven variable selection: guarding against overfitting and effects of data set size. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[42] K. Miles,et al. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival , 2012, European Radiology.
[43] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[44] D. Ettinger,et al. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program , 2011, Clinical epidemiology.
[45] M. Dewhirst,et al. Comparison of Genomics and Functional Imaging from Canine Sarcomas Treated with Thermoradiotherapy Predicts Therapeutic Response and Identifies Combination Therapeutics , 2011, Clinical Cancer Research.
[46] Balaji Ganeshan,et al. Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage , 2010, Cancer imaging : the official publication of the International Cancer Imaging Society.
[47] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Chris R Chatwin,et al. Hepatic enhancement in colorectal cancer: texture analysis correlates with hepatic hemodynamics and patient survival. , 2007, Academic Radiology.
[49] Alexander Schütz,et al. Evaluation of the invasion front pattern of squamous cell cervical carcinoma by measuring classical and discrete compactness , 2007, Comput. Medical Imaging Graph..
[50] D. Rimm,et al. X-Tile , 2004, Clinical Cancer Research.
[51] E. V. van Beek,et al. Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art. , 2017, European journal of radiology.
[52] B. Creelan. Update on immune checkpoint inhibitors in lung cancer. , 2014, Cancer control : journal of the Moffitt Cancer Center.